Karuna Therapeutics Appoints Laurie Olson to Board of Directors
August 13 2020 - 6:30AM
Business Wire
Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative
clinical-stage biopharmaceutical company committed to developing
novel therapies with the potential to transform the lives of people
with disabling and potentially fatal neuropsychiatric disorders,
today announced the appointment of Laurie Olson to its Board of
Directors effective August 12, 2020. Ms. Olson will be part of the
nominating and corporate governance committee.
“We are pleased to welcome Laurie to our board at an exciting
moment for Karuna as we continue to advance our pipeline and begin
the transition to a late-stage biotech company,” said Steve Paul,
M.D., chief executive officer, president and chairman of Karuna
Therapeutics. “Laurie’s expertise in commercial and corporate
strategy, with a keen focus on identifying and optimizing synergies
between R&D and commercial organizations, experience in growing
a culture of engaged teams, and advocacy for workplace diversity
and inclusion, will be invaluable as we navigate our next phases of
growth.”
“Karuna is making tremendous progress in advancing potential new
treatments for some of the most serious and complex
neuropsychiatric disorders,” said Ms. Olson. “I join Karuna at an
important inflection point for the company, and look forward to
working with management and the board to help grow the organization
and capabilities with the goal of delivering meaningful treatment
options to patients.”
Ms. Olson is a seasoned pharmaceutical executive with more than
30 years of commercial and corporate strategy experience, most
recently serving as the Executive Vice President, Strategy and
Commercial Operations at Pfizer Inc. until 2018. In this role, Ms.
Olson led a global organization accountable for corporate strategic
planning, portfolio management, and commercial support functions.
Ms. Olson served as a member of Pfizer’s Portfolio Strategy and
Investment Committee as well as the Pfizer Board of Directors’
Science and Technology Committee, where she was accountable for
informing therapeutic area strategies and the utilization of new
technologies and analytic methods to drive R&D and commercial
productivity. She also was a member of the Business Development,
Disclosure, Diversity, and Compliance Committees where she
supported Pfizer’s commitment to maintaining its transparency and
compliance with internal and external stakeholders. Prior to her
role as Executive Vice President, Ms. Olson held various positions
of increasing authority during her tenure at Pfizer from 1987 to
2018. She currently serves as a member of the Board of Trustees of
the Mystic Seaport Museum in Mystic, Connecticut. Ms. Olson
received a B.A. in Economics from State University of New York at
Stony Brook and an M.B.A. in Marketing from Hofstra University.
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed
to developing and delivering first-in-class therapies with the
potential to transform the lives of people with CNS disorders –
which remain among the most disabling and potentially fatal
disorders worldwide. Galvanized by the understanding that today’s
neuropsychiatric patients deserve better, Karuna’s mission is to
harness the untapped potential of the brain’s complex biology in
pursuit of novel therapeutic pathways that will advance the
standard of care. For more information, please visit
karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding our expectations about the
timing of advancing of our planned clinical trials and regulatory
filings, our goals to develop and commercialize our product
candidates, our identification of additional product candidates,
and other statements identified by words such as “could,”
“expects,” “intends,” “may,” “plans,” “potential,” “should,”
“will,” “would,” or similar expressions and the negatives of those
terms. Forward-looking statements are not promises or guarantees of
future performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to obtain necessary funding, our ability to generate positive
clinical trial results for our product candidates, the timing and
scope of regulatory approvals, changes in laws and regulations to
which we are subject, competitive pressures, our ability to
identify additional product candidates, risks relating to business
interruptions resulting from the coronavirus (COVID-19) pandemic,
and other risks set forth under the heading “Risk Factors” of our
Annual Report on Form 10-K for the year ended December 31, 2019 and
our Quarterly Report on Form 10-Q for the quarter ended June 30,
2020. Our actual results could differ materially from the results
described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200813005229/en/
Investor Contact Alexis Smith 518-338-8990
asmith@karunatx.com
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024